Plan Group Financial LLC Acquires New Holdings in Humana Inc. (NYSE:HUM)

Plan Group Financial LLC acquired a new stake in shares of Humana Inc. (NYSE:HUM) during the third quarter, HoldingsChannel.com reports. The institutional investor acquired 935 shares of the insurance provider’s stock, valued at approximately $296,000.

A number of other institutional investors also recently added to or reduced their stakes in the stock. CarsonAllaria Wealth Management Ltd. raised its stake in Humana by 111.4% in the second quarter. CarsonAllaria Wealth Management Ltd. now owns 74 shares of the insurance provider’s stock valued at $28,000 after buying an additional 39 shares during the last quarter. Atwood & Palmer Inc. purchased a new stake in Humana in the third quarter valued at about $29,000. Hantz Financial Services Inc. purchased a new stake in Humana in the second quarter valued at about $35,000. Family Firm Inc. purchased a new stake in Humana in the second quarter valued at about $37,000. Finally, Hollencrest Capital Management purchased a new stake in Humana in the second quarter valued at about $40,000. Institutional investors own 92.38% of the company’s stock.

Humana Trading Down 0.0 %

HUM opened at $262.25 on Wednesday. The business has a fifty day moving average price of $312.24 and a 200 day moving average price of $337.81. The stock has a market capitalization of $31.60 billion, a price-to-earnings ratio of 16.33, a PEG ratio of 1.91 and a beta of 0.50. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $527.18. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.66 and a quick ratio of 1.66.

Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.89 by $1.07. The business had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a return on equity of 16.12% and a net margin of 1.53%. The business’s quarterly revenue was up 10.4% compared to the same quarter last year. During the same period in the prior year, the firm posted $8.94 EPS. Sell-side analysts expect that Humana Inc. will post 16.06 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Monday, September 30th will be given a dividend of $0.885 per share. The ex-dividend date is Monday, September 30th. This represents a $3.54 annualized dividend and a dividend yield of 1.35%. Humana’s dividend payout ratio is currently 22.04%.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. KeyCorp assumed coverage on Humana in a research note on Friday, October 11th. They issued a “sector weight” rating for the company. Leerink Partners lowered Humana from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $400.00 to $250.00 in a report on Wednesday, October 2nd. Royal Bank of Canada dropped their target price on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. Cantor Fitzgerald reissued a “neutral” rating and issued a $395.00 price objective on shares of Humana in a report on Tuesday, October 1st. Finally, Jefferies Financial Group lowered Humana from a “buy” rating to a “hold” rating and dropped their price objective for the company from $519.00 to $253.00 in a report on Monday, October 7th. One analyst has rated the stock with a sell rating, nineteen have given a hold rating and six have given a buy rating to the company. According to MarketBeat.com, Humana has a consensus rating of “Hold” and an average price target of $315.33.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.